


## PHARMACEUTICAL 2017

## Corvus Pharmaceuticals Inc. Rank 17 of 292





## PHARMACEUTICAL 2017



## Corvus Pharmaceuticals Inc. Rank 17 of 292

The relative strengths and weaknesses of Corvus Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Corvus Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 97% points. The greatest weakness of Corvus Pharmaceuticals Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 18% points.

The company's Economic Capital Ratio, given in the ranking table, is 260%, being 257% points above the market average of 2.9%.

Input Variable	Value in 1000 USD
Assets, Current	136,033
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	5,944
Liabilities, Non-Current	1,405
Other Assets	869
Other Compr. Net Income	6.0
Other Expenses	0
Other Liabilities	0
Other Net Income	601
Other Revenues	0
Property and Equipment	3,248
Research and Development	29,356
Selling, General and Administrative Expense	7,620

Output Variable	Value in 1000 USD
Assets	140,150
Liabilities	7,349
Expenses	36,976
Revenues	0
Stockholders Equity	132,801
Net Income	-36,375
Comprehensive Net Income	-36,372
Economic Capital Ratio	260%

